Experts share their insights on Immunogenicity

In preparation for our inaugural Immunogenicity event (14th July – 15th July, London, UK) we spoke with our key opinion speakers

LONDON, --PLEASE SELECT--, UNITED KINGDOM, April 22, 2014 /EINPresswire.com/ -- SMi are delighted to present their inaugural Immunogenicity Conference, 14th and 15th July, Central London. Key Opinion Leaders gave interview insight - Dr Melody Sauerborn, Senior Expert Immunogenicity, TNO Triskelion focused on the fundaments in Immunology and Immunogenicity, Ronit Mazor, Research Fellow, National Cancer Institute, NIH has addressed her experience with clinical trials and the results of her study. John Chappell, Head of Immunoassay, CPR Pharma Services elaborated on the Immunogenicity of Biosimilars.

For more information on this conference please download the brochure here.

Interview insights from Key Opinion Leaders:

•Why do you think Immunogenicity is an important subject area and how will your presentation benefit the audience?

“In our clinical trials of treating mesothelioma patients with immunotoxin we found that 100% of the patients developed neutralizing antibodies after one or two cycles of treatment. The patients benefited from the drug significantly; however we could not give more drugs due to immunogenicity.
We have seen leukemia patients that did not develop immunogenicity responses (due to the nature of the disease) these patient had complete remission from their cancer.
We believe that a diminish, (even though not complete elimination) of the immunogenicity will allow more treatment cycles and benefit the patients.” - Ronit Mazor, Research Fellow, National Cancer Institute, NIH

•How do you see the future of Immunogenicity developing over the next 12 months?

“There will be a publication from the AAPS Biosimilar committee which will give the industry clear direction on how to validate assays and use these assays in support of Biosimilar drug development.
Another developing area from an immunogenicity perspective is with Antibody-Drug conjugates.” - John Chappell, Head of Immunoassay, CPR Pharma Services

•In your experience what do you feel are the main challenges in the field of Immunogenicity?

“In my opinion the harmonization of the ADA assays are a main challenge and the lack therefore currently prevents comparing results between labs. In addition, the fact that immunogenicity is semi-quantitative also impairs comparison. This is a result of the currently used positive controls, which in most cases is raised in animals who respond against the foreignness of the therapeutic and follow a wanted immunogenicity mechanism (classical immune response). In my view, the positive control is very artificial and makes data interpretation difficult. This conference offers a very broad selection of topics in addition to very well-known names in the field of immunogenicity.” - Dr Melody Sauerborn, Senior Expert Immunogenicity, TNO Triskelion

Download the full interviews here.

For more information contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum(at)smi-online(dot)co.uk

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
For more information, please visit http://www.smi-online.co.uk.

Fateja Begum
442078276184
email us here
SMi Group

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.